To date, more and more combination therapies of an anti-PD-1 antibody plus anti-angiogenesis targeted therapy have been investigated and approved as first-line systemic therapy for patients with advanced HCC (6, 7). Here, PDCD1 is linked to hepatocellular carcinoma.